MK-8527 is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) being developed for the prevention of HIV. MK-8527 shares mechanistic similarities with islatravir, offering the potential for high potency and a strong genetic barrier to resistance. MK-8527 is a promising clinical candidate for HIV PrEP, being evaluated for once-monthly oral dosing.  Two phase III trials (EXPRESSIVE-10 and EXPRESSIVE-11) are ongoing, to evaluate the use on MK-8527 11mg tablet as once monthly oral PrEP in individuals 16 years and older.

Patent & licence data in LMICs

MK-8527 on LAPaL